Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Fast-track visas

National Institute for Health and Care Excellence NICE logo

NICE backs reimbursement of Sanofi’s MS drug Lemtrada

Final guidance opens doors for use on NHS in England and Wales

- PMLiVE

NICE rejects Roche’s Kadcyla as “unaffordable”

Cancer drug unable to justify £90,000 price tag

National Institute for Health and Care Excellence NICE logo

NICE gives partial backing to Ferring’s prostate cancer drug

Firmagon on course for use on NHS in England and Wales

National Institute for Health and Care Excellence NICE logo

NICE consults on value-based assessment changes

Aims to create a more flexible approach to drug funding decisions for NHS in England and Wales

- PMLiVE

Final NICE backing for MabThera in rare condition

Roche drug available in England and Wales to treat rare form of vasculitis

National Institute for Health and Care Excellence NICE logo

Boehringer cancer drug on course for NHS use in UK

NICE backs Giotrif in draft guidance

- PMLiVE

Dawn of the new world

What the new NHS means for pharma and healthcare comms

- PMLiVE

McCarthy leaves NHS England

Policy director set for move to the University of Bradford

UK flag

UK gets its own ‘breakthrough’ status for early medicines access

But concerns remain over funding

- PMLiVE

Teva backs UK’s dementia drive with $21m investment

Pharma company will support National Institute for Health Research

National Institute for Health and Care Excellence NICE logo

NICE denies pharma influence on statin guidance

Responds to accusations committee members were ‘in the pay’ of drug firms

National Institute for Health and Care Excellence NICE logo

NICE denies pharma influence on statin guidance

Responds to accusations committee members were ‘in the pay’ of drug firms

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links